SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony,
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: baggo who wrote (42390)8/15/1999 1:27:00 PM
From: Anthony@Pacific  Read Replies (2) of 122087
 
We are in for another month of rising prices befor this meeting happens so be carefull I am watching it closesly

Moreover, Weisbord said Biocryst will present data on the flu Page 2
product at next month's at infectious-disease meetings. "I think
this will be a very pivotal," he noted in Barron's.
Biocryst stock has surged to more than twice its mid-July levels
of $9 when Johnson & Johnson announced the successful end of Phase
2 trials for the flu treatment.
Johnson & Johnson agreed to license the drug in September 1998
for $55 million, including a $12 million upfront payment and
$43 million in milestone payments, according to a Biocryst spokeswoman.
She said Biocryst will also receive undisclosed royalties after
the drug comes to market.
- Zahida Hafeez; 201-938-5176
(END) DOW JONES NEWS 08-10-99
03:43 PM
- - 03 43 PM EDT 08-10-99
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News